The Runx genes as dominant oncogenes

Blood Cells, Molecules, and Diseases

Volumn 30, Issue 2, 2003, Pages 194-200

  Cameron, Ewan R ^a   Blyth, Karen ^a   Hanlon, Linda ^a   Kilbey, Anna ^a   Mackay, Nancy ^a   Stewart, Monica ^a   Terry, Anne ^a   Vaillant, Francois ^a   Wotton, Sandy ^a   Neil, James C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

CANCER INCIDENCE; CELL LINEAGE; CELL PROLIFERATION; FIBROBLAST; GENE AMPLIFICATION; GENE FUNCTION; GENE INSERTION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; LEUKEMIA; LYMPHOMA; NONHUMAN; ONCOGENE; ONCOGENE C MYC; ONCOGENE MYB; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RUNX1 ONCOGENE; RUNX2 ONCOGENE; T LYMPHOCYTE; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALIA; MURINAE; MURINE LEUKEMIA VIRUS; MUS MUSCULUS;

EID: 0038300367     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1079-9796(03)00031-7     Document Type: Review

References (47)

1. Rini D., Calabi F. Identification and comparative analysis of a second runx3 promoter. Gene. 273:2001;13-22.
2. Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., Speck N.A. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. USA. 93:1996;3444-3449.
3. Okuda T., van Deursen J., Hiebert S.W., Grosveld G., Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 84:1996;321-330.
4. Otto F., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 89:1997;765-771. [see comments].
5. Komori T., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 89:1997;755-764. [see comments].
6. Li Q.L., et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 109:2002;113-124.
7. Levanon D., et al. The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons. EMBO J. 21:2002;3454-3463.
8. Wang S., Wang Q., Crute B.E., Melnikova I.N., Keller S.R., Speck N.A. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol. Cell. Biol. 13:1993;3324-3339.
9. Ogawa E., et al. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology. 194:1993;314-331.
10. Sasaki K., et al. Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta. Proc. Natl. Acad. Sci. USA. 93:1996;12359-12363.
11. Wang Q., et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 87:1996;697-708.
12. Miyoshi H., Shimizu K., Kozu T., Maseki N., Kaneko Y., Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl. Acad. Sci. USA. 88:1991;10431-10434.
13. Erickson P., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 80:1992;1825-1831.
14. Nisson P.E., Watkins P.C., Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet. Cytogenet. 63:1992;81-88.
15. Romana S.P., et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 85:1995;3662-3670.
16. Yergeau D.A., et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Natl. Genet. 15:1997;303-306.
17. Okuda T., et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood. 91:1998;3134-3143.
18. Song W.J., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23:1999;166-175. [see comments].
19. Osato M., et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 93:1999;1817-1824.
20. Preudhomme C., et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood. 96:2000;2862-2869.
21. Jonkers J., Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys. Acta. 1287:1996;29-57.
22. Stewart M., Terry A., O'Hara M., Cameron E., Onions D., Neil J.C. til-1 a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice . J. Gen. Virol. 77:(Pt. 3):1996;443-446.
23. Stewart M., et al. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1) evidence for a new myc collaborating oncogene . Proc. Natl. Acad. Sci. USA. 94:1997;8646-8651.
24. Vijaya S., Steffen D.L., Kozak C., Robinson H.L. Dsi-1, a region with frequent proviral insertions in Moloney murine leukemia virus-induced rat thymomas. J. Virol. 61:1987;1164-1170.
25. Stewart M., Mackay N., Cameron E.R., Neil J.C. The common retroviral insertion locus Dsil maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. J. Virol. 76:2002;4364-4369.
26. Li J., et al. Leukaemia disease genes large-scale cloning and pathway predictions . Nat. Genet. 23:1999;348-353.
27. Pozner A., et al. Transcription-coupled translation control of AML1/RUNX1 is mediated by cap- and internal ribosome entry site-dependent mechanisms. Mol. Cell. Biol. 20:2000;2297-2307.
28. Niini T., Kanerva J., Vettenranta K., Saarinen-Pihkala U.M., Knuutila S. AML1 gene amplification a novel finding in childhood acute lymphoblastic leukemia . Haematologica. 85:2000;362-366.
29. Dal Cin P., et al. Amplification of AML1 in childhood acute lymphoblastic leukemias. Genes Chromosomes Cancer. 30:2001;407-409.
30. Mikhail F.M., et al. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia. 16:2002;658-668.
31. Busson-Le Coniat M., Khac F.N., Daniel M.T., Bernard O.A., Berger R. Chromosome 21 abnormalities with AML1 amplification in acute lymphoblastic leukemia. Genes Chromosomes Cancer. 32:2001;244-249.
32. Penther D., et al. Amplification of AML1 gene is present in childhood acute lymphoblastic leukemia but not in adult, and is not associated with AML1 gene mutation. Leukemia. 16:2002;1131-1134.
33. Ma S.K., et al. Characterization of additional genetic events in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion a molecular cytogenetics study . Leukemia. 15:2001;1442-1447.
34. Martinez-Ramirez A., et al. Fluorescence in situ hybridization study of TEL/AML1 fusion and other abnormalities involving TEL and AML1 genes. Correlation with cytogenetic findings and prognostic value in children with acute lymphocytic leukemia. Haematologica. 86:2001;1245-1253.
35. Streubel B., Valent P., Lechner K., Fonatsch C. Amplification of the AML1 (CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. Cancer Genet. Cytogenet. 124:2001;42-46.
36. Vaillant F. Enforced expression of Runx2 perturbs T cell development at a stage coincident with β-selection. J. Immunol. 169:2002;2866-2874.
37. Vaillant F., et al. A full-length Cbfal gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene. 18:1999;7124-7134.
38. Blyth K., et al. Runx2 a novel oncogenic effector revealed by in vivo complementation and retroviral tagging . Oncogene. 20:2001;295-302.
39. Zaiman A.L., Lenz J. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor evidence for cooperativity with c-Myb . J. Virol. 70:1996;5618-5629.
40. Britos-Bray M., Friedman A.D. Core binding factor cannot synergistically activate the myeloperoxidase proximal enhancer in immature myeloid cells without c-Myb. Mol. Cell. Biol. 17:1997;5127-5135.
41. Kurokawa M., et al. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. Oncogene. 12:1996;883-892.
42. Cao W., et al. CBF beta-SMMHC, expressed in M4Eo AML, reduced CBF DNA-binding and inhibited the G1 to S cell cycle transition at the restriction point in myeloid and lymphoid cells. Oncogene. 15:1997;1315-1327.
43. Lou J., Cao W., Bernardin F., Ayyanathan K., Rauscher F.J. III, Friedman A.D. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene. 19:2000;2695-2703.
44. Strom D.K., et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J. Biol. Chem. 275:2000;3438-3445.
45. Bernardin F., Friedman A.D. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene. 21:2002;3247-3252.
46. Fujii M., et al. Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis. Oncogene. 17:1998;1813-1820.
47. Jenkinson E.J., Owen J.J. T-cell differentiation in thymus organ cultures. Semin. Immunol. 2:1990;51-58.